All In Biotech

Drugs by condition

Drugs approved for ovarian cancer

Brand-name prescription drugs and biologics whose FDA label lists ovarian cancer as an approved use. Matched on the label phrases: "ovarian cancer".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

14

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

8

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for ovarian cancer.

  • Axycis (Cisplatin) · Avyxa Holdings Oct 29, 2026
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Avgemsi (Gemcitabine Hydrochloride) · Avyxa Holdings Jun 27, 2025
  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 8, 2025
  • Zejula (Niraparib Tosylate) · Glaxosmithkline OrphanApr 26, 2023

All approved drugs for ovarian cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 21 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Platinum-based Drug (2)

  • Platinol-Aq Cisplatin · Hq Spclt Pharma · 1978
  • Axycis Cisplatin · Avyxa Holdings · 2026

Endoglycosidase (1)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025

Programmed Death Receptor-1 Blocking Antibody (1)

  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

Poly(ADP-Ribose) Polymerase Inhibitor (1)

  • Lynparza Olaparib · Astrazeneca · 2017

Class not listed in FDA's data (9)

Drugs in development for ovarian cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • Rina-SPRO1184, GEN1184Phase 39 trials

    Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer

  • UtidelonePhase 38 trials

    Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma

  • IBI363Phase 37 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer

  • JSKN003Phase 37 trials

    Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer

  • IpatasertibRO5532961, GDC-0068Phase 35 trials

    Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • SYS6043Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma

  • AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials

    AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • OregovomabMAb-B43.13Phase 34 trials

    CanariaBio Inc. · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Neoplasms

More on ovarian cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.